



## **LASA SUPERGENERICS LIMITED**

**CORPORATE OFFICE:** B/207, City Point, Near Kohinoor Hotel, J B Nagar (Chakala) Metro Station, Andheri (E), Mumbai – 400059, Maharashtra, India.  
Tel: 022-4970 1092, Email: mail@lasalabs.com, Website: www.lasalabs.com

**Ref. No.: LASA/SE/18-19/048**

**Monday February 11, 2019**

To, Corporate Services Department <b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. BSE CODE –540702	To, Corporate Services Department <b>National Stock Exchange of India Limited</b> “Exchange Plaza”, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. NSE CODE: LASA
--	--

Dear Sir/Madam,

**Sub. : Outcome of Board Meeting held today i.e 11 February, 2019**

Pursuant to Regulation 29 and Regulation 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we write to inform you that at the meeting held today at the Corporate Office of the Company which was commenced at 1.00 p.m. and concluded at 3.15 p.m. have considered, approved and took on record the Unaudited Financial Results for the quarter ended December 31, 2018.

A copy of the statement of Unaudited Financial Results along with Limited Review Report submitted by the Statutory Auditors of the Company is attached herewith.

The above information is also available on the company's website at [www.lasalabs.com](http://www.lasalabs.com) and on the website of the stock Exchange at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com).

Please take the same for your information and for your records.

Thanking You

**For Lasa Supergenerics Limited**

NIDHI

KULSHRESTHA

Digitally signed by  
NIDHI KULSHRESTHA  
Date: 2019.02.11  
15:29:58 +05'30'

**Nidhi Kulshreshtha**

**Company Secretary and Compliance Officer**

Encl: as above.

CIN:L24233MH2016PLC274202

**FACTORY & REGD. OFFICE:** Plot No. C-105, MIDC, Mahad, Dist. Raigad, Maharashtra, India. Tel: +91-2145-232101/ 232202

Statement of Unaudited Financial Results for the Quarter and Nine months ended 31st Dec, 2018

(Rs. In Lakhs)

Particulars	Quarter ended			Nine Months Ended		Year ended
	31.12.2018 (Unaudited)	30.09.2018 (Unaudited)	31.12.2017 (Unaudited)	31.12.2018 (Unaudited)	31.12.2017 (Unaudited)	31.03.2018 (Audited)
<b>1. INCOME</b>						
a. Revenue from Operations	5,388.38	4,074.48	6,098.61	12,754.92	18,652.70	24,583.88
b. Other Income	88.34	103.98	20.03	294.20	285.11	348.66
<b>Total Income</b>	<b>5,476.72</b>	<b>4,178.45</b>	<b>6,118.64</b>	<b>13,049.12</b>	<b>18,937.81</b>	<b>24,932.54</b>
<b>2. Expenses</b>						
a. Cost of Materials consumed	2,606.24	1,784.48	3,436.60	6,091.86	11,801.77	17,205.86
b. Cost of Traded Goods	1,582.40	1,174.13	-	3,356.31	-	-
c. Change in Inventories of Finished Goods, Work-in-Progress and Stock in trade	500.29	41.35	629.63	357.36	226.52	(55.34)
d. Excise Duty on Sales (Refer Note No.2)	-	-	-	-	231.29	231.29
e. Employee benefits expenses	297.71	285.93	259.93	851.86	754.23	1,027.09
f. Finance costs (Refer Note No.3)	193.77	397.72	377.22	952.45	872.80	1,134.35
g. Depreciation & amortizations expenses	487.22	485.07	440.71	1,452.42	1,291.34	1,816.66
h. Other Expenses	464.64	443.80	424.10	1,294.08	1,456.18	2,049.30
<b>Total Expenses (a to g)</b>	<b>6,132.27</b>	<b>4,612.48</b>	<b>5,568.18</b>	<b>14,356.33</b>	<b>16,634.12</b>	<b>23,409.21</b>
Exceptional Items	-	-	-	-	-	-
<b>3. Profit / (Loss) before tax (1-2)</b>	<b>(655.55)</b>	<b>(434.03)</b>	<b>550.46</b>	<b>(1,307.21)</b>	<b>2,303.69</b>	<b>1,523.33</b>
<b>4. Tax expense</b>						
Current Tax	-	-	147.86	-	509.76	316.33
Deferred Tax	(127.68)	(307.12)	91.20	(354.83)	(89.10)	(26.99)
Short / Excess income tax provision for earlier years	-	70.69	-	70.69	1.73	-
<b>5. Net Profit / (Loss) after tax (3-4)</b>	<b>(527.86)</b>	<b>(197.60)</b>	<b>311.40</b>	<b>(1,023.07)</b>	<b>1,881.31</b>	<b>1,233.99</b>
<b>6. Other Comprehensive Income</b>						
<b>Items that will not be reclassified into Profit or Loss</b>						
- Remeasurement of Defined Benefit Plans (Net of tax)	-	(0.38)	(0.22)	(0.38)	(1.32)	(1.42)
<b>7. Total Comprehensive Income for the year (after tax) (5+6)</b>	<b>(527.86)</b>	<b>(197.98)</b>	<b>311.19</b>	<b>(1,023.45)</b>	<b>1,879.99</b>	<b>1,232.58</b>
<b>8. Paid-up Equity Share Capital (Face Value of Re. 10/- each)</b>	<b>2,286.44</b>	<b>2,286.44</b>	<b>2,286.44</b>	<b>2,286.44</b>	<b>2,286.44</b>	<b>2,286.44</b>
<b>9. Other Equity excluding Revaluation reserve as per Balance Sheet</b>	<b>8,424.19</b>	<b>8,952.06</b>	<b>10,095.04</b>	<b>8,424.19</b>	<b>10,095.04</b>	<b>9,447.64</b>
<b>10. Earnings per Equity Share (of Rs. 10/- each)</b>						
(a) Basic	(2.31)	(0.86)	1.36	(4.47)	8.23	5.40
(b) Diluted	(2.31)	(0.86)	1.36	(4.47)	8.23	5.40
See accompanying Notes to the Financial Results						

**Notes :**

- The Above Financial Results were reviewed by the audit committee of the board on 11th February, 2019 and approved by the Board of Directors of the company at their meeting held on same date. The Statutory auditors have expressed on unmodified opinion. The review report has been filed with stock exchange and is available on the company's website. The Financial results have been prepared in accordance with Ind AS notified under the Companies (Accounting Standards) Rule, 2015.
- Post implementation of Goods and Services Tax ("GST") in India with effect from 1st July, 2017, revenue are disclosed net of GST. Revenues for the first quarter of year ended 31.03.2018 included excise duty which is now subsumed in the GST effective from 1st July 2017.
- Finance cost is net off of Rs. 79.79 Lakhs being profit on account of foreign exchange fluctuations and Rs. 24.08 Lakhs being loss on account of foreign exchange fluctuations during the quarter ended 31st December, 2018 and 31st December, 2017 respectively.
- The Company has only one reportable segment i.e. Active Pharmaceutical Ingredients (API)
- Figures of previous period have been re-grouped / reclassified wherever necessary, to confirm to this period's classification.

For Lasa Supergenerics Limited

Omkar Herlekar  
Chairman & Managing Director  
(DIN No. 01587154)



Place : Mumbai  
Date : 11th February, 2019

CIN : L24233MH2016PLC274202




**INDEPENDENT AUDITORS LIMITED REVIEW REPORT**

To,  
**THE BOARD OF DIRECTORS,  
LASA SUPERGENERICS LIMITED  
MUMBAI**

1. We have reviewed the accompanying statement of Unaudited Financial Results of **M/s.Lasa Supergenerics Limited** ("the Company"), for the quarter ended 31 December 2018 and the year-to-date result for the period from 01/04/2018 to 31/12/2018 together with the notes thereon (the "Statement"). The statement has been prepared by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by circular number CIR/CFD/FAC/62/2016 dated 05 July 2016.
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors which has been prepared in accordance with the recognition & measurement principles laid down in the Indian Accounting standard 34 "Interim Financial Reporting (Ind AS 34)" prescribed under Section 133 of the Companies Act, 2013 read with relevant Rules issued there-under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410. "Review of Interim Financial Information Performed by the Independent Auditor of the Entity," issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement.
4. A review is limited primarily to inquiries of Company personal and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
5. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement of Standalone unaudited financial result prepared in all material respect in accordance with applicable Indian Accounting Standards (Ind AS) and other recognized accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not qualified in respect of this matter.

**For Thanawala & company**  
**Chartered Accountants**  
**Firm Reg. No.: 110948W**

  
**CA Vijay K Thanawala**  
**Proprietor**  
**Membership No. 015632**  
**Mumbai, 11<sup>th</sup> February 2019**

